Study of the Response to a Neoadjuvant Chemotherapy Based on the Antitumor Immune Response in Localized Breast Cancer

Inclusion Criteria: * Histologically proven localized breast cancer required anthracycline chemotherapy +/- trastuzumab before surgery * Age \> 18 years * Chemotherapy with 3 anthracycline cycles to begin (doxorubicin or epirubicin) * Any previous treatment for this cancer * Performance Status \<= 1 * Agreement for the conservation of biological samples * Covered by an medical insurance * Signed written informed consent form * Availability of tumoral sample collected at diagnosis Exclusion Criteria: * Previous surgery for the breast cancer * Already under chemotherapy before the first blood sample * Previous Antitumoral treatment * Under immunosuppressive treatment * Under corticoids during the 15 days before enrollment * History of concomitant cancer except if it has been cured for at least 5 years * History of lymphoma or breast sarcoma * History of chronic inflammatory disease or autoimmune disease, hepatitis B or C or immune dysfunction disease (including HIV-positive stage AIDS) known * History of other disease which is discrepant with this study * Deprived of liberty by court or administrative decision * Pregnant or breastfeeding women or with no use of effective birth control methods for women of childbearing potential